1. Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing
- Author
-
Deirdre O’Meara, Bo Hejdeman, Karin Wilbe, Thomas Leitner, Joakim Lundeberg, and Jan Albert
- Subjects
Adult ,Male ,Microbiology (medical) ,Time Factors ,HIV Infections ,Drug resistance ,Biology ,Virus Replication ,Polymerase Chain Reaction ,Virus ,law.invention ,HIV Protease ,law ,Virology ,Antiretroviral Therapy, Highly Active ,Humans ,HIV Protease Inhibitor ,Protease inhibitor (pharmacology) ,Codon ,Polymerase chain reaction ,DNA Primers ,Salvage Therapy ,Genetics ,Acquired Immunodeficiency Syndrome ,Polymorphism, Genetic ,Base Sequence ,Drug Resistance, Microbial ,HIV Protease Inhibitors ,Middle Aged ,Reverse transcriptase ,DNA, Viral ,HIV-1 ,Pyrosequencing ,Female ,Viral load ,Follow-Up Studies - Abstract
The emergence of drug-resistant viral variants is the inevitable consequence of incomplete suppression of human immunodeficiency virus type 1 (HIV-1) replication during treatment with antiretroviral drugs. Sequencing to determine the resistance profiles of these variants has become increasingly important in the clinical management of HIV-1 patients, both in the initial design of a therapeutic plan and in selecting a salvage regimen. Here we have developed a pyrosequencing assay for the rapid characterization of resistance to HIV-1 protease inhibitors (PIs). Twelve pyrosequencing primers were designed and were evaluated on the MN strain and on viral DNA from peripheral blood mononuclear cells from eight untreated HIV-1-infected individuals. The method had a limit of detection of 20 to 25% for minor sequence variants. Pattern recognition (i.e., comparing actual sequence data with expected wild-type and mutant sequence patterns) simplified the identification of minor sequence variants. This real-time pyrosequencing method was applied in a longitudinal study monitoring the development of PI resistance in plasma samples obtained from four patients over a 2 1/2-year period. Pyrosequencing identified eight primary PI resistance mutations as well as several secondary mutations. This sequencing approach allows parallel analysis of 96 reactions in 1 h, facilitating the monitoring of drug resistance in eight patients simultaneously and, in combination with viral load analysis, should be a useful tool in the future to monitor HIV-1 during therapy.
- Published
- 2001
- Full Text
- View/download PDF